FOLH1 and thyroid cancer: Centers reported decreases in radioiodine therapy for thyroid cancer and benign diseases by an average of 47% and 63%, respectively, whereas radiosynovectomies decreased by 43%, selective internal radiation therapy by 40%, peptide receptor radionuclide therapy by 38%, and prostate-specific membrane antigen radioligand therapy by 38%, respectively.